MORIHITO OKADA

Last Updated :2024/05/15

Affiliations, Positions
Research Institute for Radiation Biology and Medicine, Professor
E-mail
morihito1217gmail.com

Basic Information

Academic Degrees

  • Doctor of Philosophy in Medical Science, Kobe University

Research Fields

  • Medicine,dentistry, and pharmacy;Clinical surgery;Respiratory surgery

Educational Activity

Course in Charge

  1. 2024, Undergraduate Education, Year, Clinical diagnosis and treatment I
  2. 2024, Undergraduate Education, Year, Systemic Disease Control
  3. 2024, Undergraduate Education, Intensive, Practice for medical research
  4. 2024, Undergraduate Education, Intensive, Practice of Medicine I
  5. 2024, Undergraduate Education, Intensive, Practice of Medicine II
  6. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Surgical Oncology
  7. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Surgical Oncology
  8. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Research on Surgical Oncology
  9. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Research on Surgical Oncology
  10. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Breast Cancer Treatment
  11. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Breast Cancer Treatment
  12. 2024, Graduate Education (Doctoral Program) , First Semester, Advanced Seminar on Surgical Oncology
  13. 2024, Graduate Education (Doctoral Program) , Second Semester, Advanced Seminar on Surgical Oncology

Research Activities

Academic Papers

  1. Risk factors for recurrence of stage I epidermal growth factor receptor mutated lung adenocarcinoma, Ann Thorac Surg, 49(13), 1891-1892, 202212
  2. Segmentectomy for Spread Through Air Spaces-positive Lung Adenocarcinoma, Ann Thorac Surg, 114(5), 1989-1990, 202211
  3. The impact of epidermal growth factor receptor mutation status on adjuvant chemotherapy for patients with high-risk stage I lung adenocarcinoma, J Thorac Cardiovasc Surg, 164(5), 1306-1315.e4, 202211
  4. Committee for Scientific Affairs, The Japanese Association for Chest Surgery. The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303, Surg Today, 52(10), 1463-1471, 202210
  5. Commentary: Segmentectomy as a standard surgery, a new era in small sized, peripheral, non-small cell lung cancer, JTCVS Tech, 20(12), 210-211, 20220220
  6. Psychological states regarding adjuvant chemotherapy in patients with non-small cell lung cancer, Cancer Treat Res Commun, 23(5), 393-401, 202207
  7. Complications and Survival After Lung Cancer Resection in Interstitial Lung Disease, Ann Thorac Surg, 115(3), 701-708, 202303
  8. Advanced Clinical Trial Chest Surgery Group (ACTG).S-1 + Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial, Ann Surg Oncol, 29(13), 8198-8206, 20221229
  9. Role of ground-glass opacity in pure invasive and lepidic component in pure solid lung adenocarcinoma for predicting aggressiveness, JTCVS Open, 2(11), 300-316, 202205
  10. Discrepancy Between Radiological and Pathological Tumor Size in Early-Stage Non-Small Cell Lung Cancer: A Multicenter Study, Semin Thorac Cardiovasc Surg, S1043-0679(22), 00277-5, 20221210
  11. First-line nivolumab plus ipilimumab or chemotherapy versus chemotherapy alone in advanced esophageal squamous cell carcinoma: a Japanese subgroup analysis of open-label, phase 3 trial (CheckMate 648/ONO-4538-50), ESOPHAGUS, 20(2), 291-301, 20221119
  12. Effectiveness of taxanes following nivolumab in patients with advanced esophageal squamous cell carcinoma: a retrospective chart review of patients in ATTRACTION-3, ESOPHAGUS, 202212
  13. Blood biomarkers as predictors of pathological lymph node metastasis in clinical stage T1N0 esophageal squamous cell carcinoma, DISEASES OF THE ESOPHAGUS, 36(1), 20221231
  14. Bevacizumab plus erlotinib versus erlotinib alone in Japanese patients with advanced, metastatic, EGFR-mutant non-small-cell lung cancer (NEJ026): overall survival analysis of an open-label, randomised, multicentre, phase 3 trial, LANCET RESPIRATORY MEDICINE, 10(1), 72-82, 202201
  15. Impact of the amount of preoperative erector spinae muscle in stage I non-small-cell lung cancer, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 63(1), 20221202
  16. Effect of Secondary Prophylactic G-CSF on the Occurrence of Febrile Neutropenia in Breast Cancer, ANTICANCER RESEARCH, 42(12), 5945-5949, 202212
  17. Correlation Between Tumor Uptake on FDG-PET and Malignant Features in Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery, ANTICANCER RESEARCH, 42(12), 6037-6045, 202212
  18. The intersegmental pulmonary vein is not always located on the intersegmental plane of the lung: Evaluation with 3-dimensional volume-rendering image reconstruction, JTCVS TECHNIQUES, 16, 132-138, 202212
  19. Adjuvant atezolizumab in Japanese patients with resected stage IB-IIIA non-small cell lung cancer (IMpower010), CANCER SCIENCE, 113(12), 4327-4338, 202212
  20. Segmentectomy for clinically early-stage primary squamous cell carcinoma of the lung, THORACIC CANCER, 13(24), 3477-3485, 202212
  21. Leukocyte Telomeric G-Tail Length Shortening Is Associated with Esophageal Cancer Recurrence, JOURNAL OF CLINICAL MEDICINE, 11(24), 202212
  22. Prevalence of immune-related adverse events and anti-tumor efficacy following immune checkpoint inhibitor therapy in Japanese patients with various solid tumors, BMC CANCER, 22(1), 20221129
  23. S-1+Cisplatin with Concurrent Radiotherapy Followed by Surgery for Stage IIIA (N2) Lung Squamous Cell Carcinoma: Results of a Phase II Trial, ANNALS OF SURGICAL ONCOLOGY, 29(13), 8198-8206, 202212
  24. Randomized phase II trial of pemetrexed-cisplatin plus bevacizumab or thoracic radiotherapy followed by surgery for stage IIIA (N2) nonsquamous non-small cell lung cancer, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 164(3), 661-+, 202209
  25. The tumor-infiltrating lymphocyte ultrasonography score can provide a diagnostic prediction of lymphocyte-predominant breast cancer preoperatively, JOURNAL OF MEDICAL ULTRASONICS, 49(4), 709-717, 202210
  26. Prognostic Factors for Patients With Esophageal Squamous Cell Carcinoma After Neoadjuvant Chemotherapy Followed by Surgery, IN VIVO, 36(6), 2852-2860, 2022
  27. The C-reactive protein to albumin ratio is a prognostic factor for stage I non-small cell lung cancer in elderly patients: JACS1303, SURGERY TODAY, 52(10), 1463-1471, 202210
  28. Prognostic value of quantitative parameters for esophageal squamous cell carcinoma determined by preoperative FDG-PET after trimodal therapy, SURGERY, 172(2), 584-592, 202208
  29. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma., J Cancer Res Clin Oncol, 20210703
  30. Dual-phase FDG PET/CT for predicting prognosis in operable breast cancer, BREAST, 65, 98-103, 202210
  31. The prognostic impact of the ground-glass opacity component in nearly pure-solid stage IA non-small-cell lung cancer, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 62(3), 20220803
  32. Phase I Study of Tremelimumab Monotherapy or in Combination With Durvalumab in Japanese Patients With Advanced Solid Tumors or Malignant Mesothelioma, ONCOLOGIST, 27(9), E703-E722, 20220902
  33. A Multicenter Study of Complex Segmentectomy Versus Wedge Resection in Clinical Stage 0-IA Non-Small Cell Lung Cancer, CLINICAL LUNG CANCER, 23(5), 393-401, 202207
  34. Possible Therapeutic Utility of anti-Cell Adhesion Molecule 1 Antibodies for Malignant Pleural Mesothelioma, FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 10, 20220712
  35. Oncological outcome of segmentectomy for early-stage non-small-cell lung cancer with invasive characteristics: a multicentre study, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 62(2), 20220711
  36. Neoadjuvant pemetrexed plus cisplatin followed by pleurectomy for malignant pleural mesothelioma, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 163(6), 1940-+, 202206
  37. Three-Year Follow-Up and Response-Survival Relationship of Nivolumab in Previously Treated Patients with Advanced Esophageal Squamous Cell Carcinoma (ATTRACTION-3), CLINICAL CANCER RESEARCH, 28(15), 20220801
  38. Complex Segmentectomy for Hypermetabolic Clinical Stage IA Non-Small Cell Lung Cancer, ANNALS OF THORACIC SURGERY, 113(4), 1317-1324, 202204
  39. Japanese Current Status of Curative-Intent Surgery for Malignant Pleural Mesothelioma, ANNALS OF THORACIC SURGERY, 113(4), 1348-1353, 202204
  40. Evaluation of Neoadjuvant Chemoradiotherapy Followed by Surgery for Borderline Resectable Esophageal Squamous Cell Carcinoma, WORLD JOURNAL OF SURGERY, 46(8), 1934-1943, 202208
  41. Adjuvant Chemotherapy for High-risk Pathologic Stage I Non-Small Cell Lung Cancer, ANNALS OF THORACIC SURGERY, 113(5), 1608-1616, 202205
  42. Role of Soluble Receptor for Advanced Glycation End Products in Postoperative Fibrotic Lung Injury, ANNALS OF THORACIC SURGERY, 113(5), 1617-1623, 202205
  43. The TILs-US score on ultrasonography can predict the pathological response to neoadjuvant chemotherapy for human epidermal growth factor receptor 2-positive and triple-negative breast cancer, SURGICAL ONCOLOGY-OXFORD, 41, 202205
  44. Clinical Outcomes of Esophagectomy and Chemoradiotherapy After Endoscopic Resection for Superficial Esophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 42(5), 2791-2795, 202205
  45. Segmentectomy versus lobectomy in small-sized peripheral non-small-cell lung cancer (JCOG0802/WJOG4607L) : a multicentre, open-label, phase 3, randomised, controlled, non-inferiority trial, LANCET, 399(10335), 1607-1617, 20220423
  46. Prognostic Impact of Mediastinal Lymph Node Dissection in Octogenarians With Lung Cancer: JACS1303, CLINICAL LUNG CANCER, 23(3), E176-E184, 202205
  47. Randomized Phase III Study of Gefitinib Versus Cisplatin Plus Vinorelbine for Patients With Resected Stage II-IIIA Non-Small-Cell Lung Cancer With EGFR Mutation (IMPACT), JOURNAL OF CLINICAL ONCOLOGY, 40(3), 231-+, 20220120
  48. The ratio of CD8+lymphocytes to tumor-infiltrating suppressive FOXP3+effector regulatory T cells is associated with treatment response in invasive breast cancer, DISCOVER ONCOLOGY, 13(1), 20220419
  49. Interstitial pneumonia and advanced age negatively influence postoperative pulmonary function, INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 34(5), 753-759, 20220502
  50. Segmentectomy versus wedge resection for radiological solid predominant and low metabolic non-small cell lung cancer, INTERACTIVE CARDIOVASCULAR AND THORACIC SURGERY, 34(5), 814-821, 20220502
  51. Exploratory Analysis Comparing Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting (CINV): A Randomized, Double-Blind, Phase 3 Study (CONSOLE), ONCOLOGY AND THERAPY, 10(1), 253-262, 202206
  52. Sensitivity and optimal clinicopathological features for mutation-targeted liquid biopsy in pN0M0 EGFR-mutant lung adenocarcinoma, JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 148(6), 1419-1428, 202206
  53. Recurrent esophageal adenocarcinoma derived from ectopic gastric mucosa: A case report, THORACIC CANCER, 13(6), 876-879, 202203
  54. Neutrophil-to-Lymphocyte Ratio as a Predictor of Postoperative Recurrence and Prognosis in Oesophageal Squamous Cell Carcinoma, ANTICANCER RESEARCH, 42(3), 1499-1507, 202203
  55. Prognostic biomarker study in patients with clinical stage I esophageal squamous cell carcinoma: JCOG0502-A1, CANCER SCIENCE, 113(3), 1018-1027, 202203
  56. Segmentectomy versus lobectomy for solid predominant cN0 lung cancer: analysis using visual evaluation of positron emission tomography, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 61(2), 279-286, 20220124
  57. Prognostic significance of using solid versus whole tumor size on high-resolution computed tomography for predicting pathologic malignant grade of tumors in clinical stage IA lung adenocarcinoma: A multicenter study, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 143(3), 607-612, 201203
  58. Metabolomic analysis of dynamic response and drug resistance of gastric cancer cells to 5-fluorouracil, ONCOLOGY REPORTS, 29(3), 925-931, 201303
  59. Esophageal Bypass Operation Prior to Definitive Chemoradiotherapy in Advanced Esophageal Cancer With Tracheobronchial Invasion, ANNALS OF THORACIC SURGERY, 97(1), 290-295, 201401
  60. Emergency escape surgery for a gastro-bronchial fistula with respiratory failure that developed after esophagectomy, Surgery Today, 45(3), 369-373, 201503
  61. Effects of neoadjuvant chemoradiotherapy on postoperative morbidity and mortality associated with esophageal cancer, DISEASES OF THE ESOPHAGUS, 28(4), 358-364, 2015
  62. Utility of F-18 FDG-PET/CT for predicting prognosis of luminal-type breast cancer, BREAST CANCER RESEARCH AND TREATMENT, 150(1), 209-217, 201502
  63. Comparison of Malignant Grade Between Pure and Partially Invasive Types of Early Lung Adenocarcinoma, ANNALS OF THORACIC SURGERY, 99(3), 956-960, 201503
  64. The Efficacy and Safety of Preoperative Chemotherapy With Triweekly Abraxane and Cyclophosphamide Followed by 5-Fluorouracil, Epirubicin, and Cyclophosphamide Therapy for Resectable Breast Cancer: A Multicenter Clinical Trial, CLINICAL BREAST CANCER, 15(2), 110-116, 201504
  65. The Rho GTPase Rnd1 suppresses mammary tumorigenesis and EMT by restraining Ras-MAPK signalling, NATURE CELL BIOLOGY, 17(1), 81-+, 201501
  66. Methylated DLX4 Predicts Response to Pathologic Stage I Non-Small Cell Lung Cancer Resection, ANNALS OF THORACIC SURGERY, 99(5), 1746-1754, 201505
  67. Histologic changes associated with the use of fibrinogen- and thrombin-impregnated collagen in the prevention of pulmonary air leakage, JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY, 149(4), 982-988, 201504
  68. What are the radiologic findings predictive of indolent lung adenocarcinoma?, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45(4), 367-372, 201504
  69. Surgical outcomes of non-small-cell lung carcinoma in patients previously treated for gastric cancer, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 47(4), 648-652, 201504
  70. Prediction of lymph node status in clinical stage IA squamous cell carcinoma of the lung, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 47(6), 1022-1026, 201506
  71. Results of Neoadjuvant Chemoradiotherapy With Docetaxel and 5-Fluorouracil Followed by Esophagectomy to Treat Locally Advanced Esophageal Cancer, ANNALS OF THORACIC SURGERY, 99(6), 1887-1893, 201506
  72. Increased ectodomain shedding of cell adhesion molecule 1 as a cause of type II alveolar epithelial cell apoptosis in patients with idiopathic interstitial pneumonia, RESPIRATORY RESEARCH, 16, 20150801
  73. The intracellular domain of cell adhesion molecule 1 is present in emphysematous lungs and induces lung epithelial cell apoptosis, JOURNAL OF BIOMEDICAL SCIENCE, 22, 20150811
  74. Radiologic findings to predict low-grade malignant tumour among clinical T1bN0 lung adenocarcinomas: lessons from histological subtypes, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45(8), 767-773, 201508
  75. Randomized phase II study of adjuvant chemotherapy with long-term S-1 versus cisplatin+S-1 in completely resected stage II-IIIA non-small cell lung cancer., Clinical cancer research, 20150807
  76. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma., Lung Cancer, 90(2), 199-204, 201511
  77. Prognostic signature of protocadherin 10 methylation in curatively resected pathological stage I non-small-cell lung cancer, CANCER MEDICINE, 4(10), 1536-1546, 201510
  78. The Difference in Maximum Standardized Uptake Value among Lung Adenocarcinomas Located at the Upper and Lower Zone on PET/CT, RESPIRATION, 90(4), 293-298, 2015
  79. Prognostic value of the new IASLC/ATS/ERS classification of clinical stage IA lung adenocarcinoma, LUNG CANCER, 90(2), 199-204, 201511
  80. Randomized Phase II Study of Adjuvant Chemotherapy with Long-term S-1 versus Cisplatin+S-1 in Completely Resected Stage II-IIIA Non-Small Cell Lung Cancer, CLINICAL CANCER RESEARCH, 21(23), 5245-5252, 20151201
  81. Impact of Lepidic Component Occupancy on Effects of Adjuvant Chemotherapy for Lung Adenocarcinoma, ANNALS OF THORACIC SURGERY, 100(6), 2079-2086, 201512
  82. Surgical Outcomes of Lung Cancer in Patients with Combined Pulmonary Fibrosis and Emphysema, ANNALS OF SURGICAL ONCOLOGY, 22, S1371-S1379, 201512
  83. Association between [F-18]-fluoro-2-deoxyglucose uptake and expressions of hypoxia-induced factor 1 alpha and glucose transporter 1 in non-small cell lung cancer, JAPANESE JOURNAL OF CLINICAL ONCOLOGY, 45(12), 1154-1161, 201512
  84. Negative prognostic influence of micropapillary pattern in stage IA lung adenocarcinoma, EUROPEAN JOURNAL OF CARDIO-THORACIC SURGERY, 49(1), 293-299, 201601
  85. Use of Anti-Noxa Antibody for Differential Diagnosis between Epithelioid Mesothelioma and Reactive Mesothelial Hyperplasia, PATHOBIOLOGY, 83(1), 33-40, 2016
  86. Bevacizumab beyond disease progression after first-line treatment with bevacizumab plus chemotherapy in advanced nonsquamous non-small cell lung cancer (West Japan Oncology Group 5910L): An open-label, randomized, phase 2 trial, CANCER, 122(7), 1050-1059, 20160401
  87. Surgical Resection of Thoracic Esophageal Cancer with Interstitial Lung Disease: A Case Report., Hiroshima journal of medical sciences, 65(1), 19-23, 2016
  88. Completion lobectomy after radical segmentectomy for pulmonary malignancies., Asian cardiovascular & thoracic annals, 24(5), 450-454, 2016
  89. Preoperative Cumulative Smoking Dose on Lung Cancer Surgery in a Japanese Nationwide Database, ANNALS OF THORACIC SURGERY, 113(1), 237-243, 202201
  90. A risk model for prolonged air leak after lobectomy using the National Clinical Database in Japan, SURGERY TODAY, 52(1), 69-74, 202201
  91. Malignant prediction of incidental findings using ring-type dedicated breast positron emission tomography, SCIENTIFIC REPORTS, 12(1), 20220121
  92. Randomized, Double-Blind, Phase III Study of Fosnetupitant Versus Fosaprepitant for Prevention of Highly Emetogenic Chemotherapy-Induced Nausea and Vomiting: CONSOLE, JOURNAL OF CLINICAL ONCOLOGY, 40(2), 180-+, 20220110
  93. p Clinical Behavior of Combined Versus Pure High-Grade Neuroendocrine Carcinoma, CLINICAL LUNG CANCER, 23(1), E9-+, 202201

Publications such as books

  1. 2012, Illustrated Anatomical Segmentectomy for Lung Cancer, Nomori,Hiroaki Okada,Morihito

Social Activities

History as Peer Reviews of Academic Papers

  1. Journal of Clinical Oncology
  2. Journal of Thoracic and Cardiovascular Surgery
  3. Chest
  4. Annals of Thoracic Surgery
  5. European Journal of Cardiothoracic Surgery
  6. Lung Cancer
  7. Journal of Thoracic Oncology
  8. Surgery Today
  9. Cancer Science
  10. Japanese Journal of Clinical Oncology, Editor
  11. General Thoracic and Cardiovascular Surgery, Editor